Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known...

Full description

Saved in:
Bibliographic Details
Published in:Cellular & molecular immunology Vol. 17; no. 6; pp. 613 - 620
Main Authors: Tai, Wanbo, He, Lei, Zhang, Xiujuan, Pu, Jing, Voronin, Denis, Jiang, Shibo, Zhou, Yusen, Du, Lanying
Format: Journal Article
Language:English
Published: China Nature Publishing Group 01.06.2020
Subjects:
ACE2
Amino Acid Sequence
Angiotensin
Angiotensin-converting enzyme 2
Animals
Antibodies
Antibodies, Viral - immunology
Antisera
Betacoronavirus - immunology
Betacoronavirus - metabolism
Binding Sites
Chiroptera
Coronaviridae
Coronavirus Infections - immunology
Coronavirus Infections - metabolism
Coronavirus Infections - prevention & control
Coronavirus Infections - therapy
Coronavirus Infections - virology
Coronaviruses
COVID-19
COVID-19 Vaccines
Cross Reactions
HEK293 Cells
Humans
Infections
Mice
Pandemics
Peptidyl-dipeptidase A
Pneumonia, Viral - immunology
Pneumonia, Viral - metabolism
Pneumonia, Viral - therapy
Pneumonia, Viral - virology
Protein Binding
Proteins
Public health
Receptor, Angiotensin, Type 2 - metabolism
SARS Virus - immunology
SARS Virus - metabolism
SARS-CoV-2
Sequence Alignment
Severe acute respiratory syndrome coronavirus 2
Spike Glycoprotein, Coronavirus - metabolism
Vaccines
Viral Vaccines - immunology
Viral Vaccines - metabolism
Virus attachment
Virus Internalization
SARS-CoV-2
cross-neutralization
2019 novel coronavirus
viral inhibitor
receptor-binding domain
spike protein
ISSN:1672-7681, 2042-0226, 2042-0226
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The outbreak of Coronavirus Disease 2019 (COVID-19) has posed a serious threat to global public health, calling for the development of safe and effective prophylactics and therapeutics against infection of its causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as 2019 novel coronavirus (2019-nCoV). The CoV spike (S) protein plays the most important roles in viral attachment, fusion and entry, and serves as a target for development of antibodies, entry inhibitors and vaccines. Here, we identified the receptor-binding domain (RBD) in SARS-CoV-2 S protein and found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors. SARS-CoV-2 RBD exhibited significantly higher binding affinity to ACE2 receptor than SARS-CoV RBD and could block the binding and, hence, attachment of SARS-CoV-2 RBD and SARS-CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. SARS-CoV RBD-specific antibodies could cross-react with SARS-CoV-2 RBD protein, and SARS-CoV RBD-induced antisera could cross-neutralize SARS-CoV-2, suggesting the potential to develop SARS-CoV RBD-based vaccines for prevention of SARS-CoV-2 and SARS-CoV infection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1672-7681
2042-0226
2042-0226
DOI:10.1038/s41423-020-0400-4